Abstract This paper examines the complex pathophysiological mechanisms underlying extreme somatic hypersensitivity to low-dose nicotine, mimicking presentations of Cyclic Vomiting Syndrome (CVS). While typically characterized by acute toxic profiles, certain patient populations exhibit a profound, prolonged neuro-inflammatory and gastrointestinal response to minimal alkaloid exposure. This paper hypothesizes that this clinical phenotype is driven by a primary baseline of dysautonomia and Mast Cell Activation Syndrome (MCAS), wherein nicotine serves as a potent destabilizing trigger. This autonomic imbalance is chronically exacerbated by genetic variations in the cytochrome P450 2A6 (CYP2A6) enzyme, which delays metabolic clearance. The resulting prolonged receptor binding drives severe vagal nerve dysfunction and gastrointestinal dysmotility. Keywords: Nicotine hypersensitivity, dysautonomia, mast cell activation syndrome, CYP2A6, vagus nerve, cyclic vomiting 2nd paper: Abstract This paper explores the complex neuro-behavioral and physiological feedback loops that drive chronic nicotine use in patients with underlying dysautonomia and Mast Cell Activation Syndrome (MCAS). Rather than viewing nicotine dependence purely through the lens of primary addiction, this paper frames it as a compensatory, yet volatile, attempt at manual autonomic regulation. Driven by an underlying neuro-immune destabilization—rooted in post-viral syndromes, latent autoimmunity, connective tissue laxity, or environmental toxic load—patients utilize the acute vasoconstrictive and stimulatory properties of nicotine to temporarily stabilize systemic chaos [5]. However, due to genetic metabolic impairments (CYP2A6 polymorphisms) and localized mast cell degranulation along the vagus nerve, this manual intervention triggers severe, delayed cyclical vomiting and neuro-inflammatory flares [1, 2]. This creates an intermittent reinforcement schedule (a "Skinner box" effect) and a paradoxical withdrawal loop where the drug temporarily numbs the exact somatic distress it actively generates [3, 4]. A comprehensive clinical roadmap must therefore prioritize stabilizing the underlying neuro-immune axis before attempting nicotine cessation [5]. Keywords: Dysautonomia, MCAS, manual regulation, nicotine withdrawal, Skinner box, neuro-inflammation, clinical roadmap. 3rd paper: Abstract This paper expands upon the model of nicotine-induced manual regulation by identifying the upstream, environmental drivers of baseline dysautonomia and Mast Cell Activation Syndrome (MCAS). It hypothesizes that modern industrial food additives, pesticide residues, and immunogenic biological pharmaceuticals serve as primary environmental toxins that degrade the gut barrier, trigger systemic mast cell degranulation, and induce structural neuro-inflammation. Consequently, Irritable Bowel Syndrome (IBS) is reframed not as a localized gastrointestinal disease, but as a direct downstream manifestation of low vagal tone and mast-cell-driven enteric dysmotility. Furthermore, this chronic neuro-inflammatory axis is explored as an environmental primer for central nervous system demyelination, specifically Multiple Sclerosis (MS). Special attention is paid to chemical food additives, pesticide vectors, carbohydrate fermentation failure, and the controversial role of hyper-immunization as systemic neuro-immune triggers. 4th paper: Abstract This paper extends the environmental neuro-immune model by examining the pathophysiology of Amyotrophic Lateral Sclerosis (ALS). While historically viewed through a strict, intrinsic motor-centric lens, contemporary research repositions ALS as a non-cell-autonomous disease heavily mediated by chronic peripheral inflammation. Specifically, this paper models how industrial food and agricultural neurotoxins induce systemic mast cell activation and a measurable bilateral atrophy of the vagus nerve. The loss of vagal parasympathetic control uncaps peripheral immune cells, allowing c-Kit+ mast cells to migrate into the spinal cord parenchyma, degranulate along motor nerve terminals, and accelerate Wallerian degeneration. Ultimately, this places ALS at the terminal end of the environmental toxification spectrum, reinforcing the clinical imperative to address upstream environmental and autonomic stability. [6]